The anthrax vaccine and research: Reactions from postal workers and public health professionals

Biosecurity and Bioterrorism

Volumn 6, Issue 4, 2008, Pages 321-333

  Quinn, Sandra Crouse ^a   Thomas, Tammy ^a   Kumar, Supriya ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BIOLOGICAL WARFARE; FEMALE; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; INTERVIEW; MALE; MIDDLE AGED; PATIENT ATTITUDE; POSTAL MAIL; PUBLIC HEALTH; RESEARCH; TRUST; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ANTHRAX VACCINES; BIOTERRORISM; COMMUNICATION; FEMALE; FOCUS GROUPS; HUMANS; INFORMED CONSENT; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POSTAL SERVICE; PUBLIC HEALTH; RESEARCH; TRUST; UNITED STATES;

EID: 58149236971     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2007.0064     Document Type: Article

References (81)

1. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002 Oct;8(10):1019-1028.
2. U.S. Centers for Disease Control and Prevention. Evaluation of Bacillus anthracis contamination inside the Brentwood Mail Processing and Distribution Center-District of Columbia, October 2001. MMWR Morb Mortal Wkly Rep 2001;50(50):1129-1133.
3. Greene CM, Reefhuis J, Tan C, et al. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg Infect Dis 2002 Oct;8(10): 1048-1055.
4. Tan CG, Sandhu HS, Crawford DC, et al. Surveillance for anthrax cases associated with contaminated letters, New Jersey, Delaware, and Pennsylvania, 2001. Emerg Infect Dis 2002 Oct;8(10):1073-1077.
5. U.S. Government Accountability Office. U.S. Postal Service: Better Guidance Is Needed to Ensure an Appropriate Response to Anthrax Contamination. Washington, DC: GAO; 2004.
6. U.S. Centers for Disease Control and Prevention. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002;51 (45): 1024-1026.
7. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999 May 12;281(18):1735-1745.
8. U.S. Centers for Disease Control and Prevention. Interim guidelines for investigation of and response to Bacillus anthracis exposures. MMWR Morb Mortal Wkly Rep 2001;50(44):987-990.
9. U.S. Centers for Disease Control and Prevention. CDC responds: an update on treatment options for postal and other workers exposed to anthrax [transcript]. http://emergency.cdc.gov/DocumentsApp/Anthrax/12212001/ postalworkers.pdf. Updated December 27, 2001. Accessed November 2, 2008.
10. U.S. Centers for Disease Control and Prevention. Notice to readers: additional options for preventive treatment of persons exposed to inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001;50(50):1142-1151.
11. U.S. Department of Defense. Anthrax vaccine immunization program. http://www.anthrax.osd.mil/vaccine/schedule.asp. Accessed November 2, 2008.
12. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002 Oct;8(10): 1124-1132.
13. U.S. Centers for Disease Control and Prevention. Backgrounder and advisory. http://www.cdc.gov/od/oc/media/pressrel/b011221.htm. Updated December 21, 2001. Accessed March 28, 2008.
14. U.S. Food and Drug Administration. Guidance Emergency Use Authorization of Medical Products. Rockville, MD: Office of Counterterrorism Policy and Planning; 2007. http://www.fda.gov/oc/guidance/emergencyuse.html. Accessed November 2, 2008.
15. Nightingale SL, Prasher JM, Simonson S. Emergency Use Authorization (EUA) to enable use of needed products in civilian and military emergencies, United States. Emerg Infect Dis 2007;13(7):1046-105l.
16. Brewer NT, Hallman WK. Subjective and objective risk as predictors of influenza vaccination during the vaccine shortage of 2004-2005. Clin Infect Dis 2006 Dec 1;43(11):1379-1386.
17. Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998-2005: inevitable community outrage or a failure of risk communication? Vaccine 2006 May 1;24(18):3921-3928.
18. Coins WP, Schaffner W, Edwards KM, Talbot TR. Healthcare workers' knowledge and attitudes about pertussis and pertussis vaccination. Infect Control Hosp Epidemiol 2007 Nov;28(11):1284-1289.
19. Petts J, Niemeyer S. Health risk communication and amplification: learning from the MMR vaccination controversy. Health Risk Soc 2004;6(1):7-23.
20. Samoff E, Dunn A, VanDevanter N, Blank S, Weisfuse IB. Predictors of acceptance of hepatitis B vaccination in an urban sexually transmitted diseases clinic. Sex Transm Dis 2004 Jul;31(7):415-420.
21. Skowronski DM, Pielak K, Remple VP, et al. Adult tetanus, diphtheria and pertussis immunization: knowledge, beliefs, behavior and anticipated uptake. Vaccine 2004 Dec 2;23(3):353-361.
22. Benin AL, Dembry L, Shapiro ED, Holmboe ES. Reasons physicians accepted or declined smallpox vaccine, February through April, 2003. J Gen Intern Med 2004 Jan;19(1):85-89.
23. Everett WW, Coffin SE, Zaoutis T, Halpern SD, Strom BL. Smallpox vaccination: a national survey of emergency health care providers. Acad Emerg Med 2003 Jun;10(6):606-611.
24. Kwon N, Raven MC, Chiang WK, et al. Emergency physicians' perspectives on smallpox vaccination. Acad Emerg Med 2003 Jun;10(6):599-605.
25. Fowler GL, Baggs JM, Weintraub ES, Martin SW, McNeil MM, Gust DA. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. Pharmacoepidemiol Drug Saf 2006 Dec;15(12):880-888.
26. Reynolds B. Introduction to Crisis and Emergency Risk Communication. Crisis and Emergency Risk Communication. Atlanta, GA: Centers for Disease Control and Prevention; 2002:1-12.
27. Caiman KC. Communication of risk: choice, consent, and trust. Lancet 2002 Jul 13;360(9327);166-168.
28. Leask J. Vaccination and risk communication: summary of a workshop, Arlington Virginia, USA, 5-6 October 2000. J Paediatr Child Health 2002 Apr;38(2):124-128.
29. MacIntyre CR, Leask J, Immunization myths and realities: responding to arguments against immunization. J Paediatr Child Health 2003 Sep-Oct;39(7):487-491.
30. Stoto MA, Evans G, Bostrom A. Vaccine risk communication. Am J Prev Med 1998 Apr;14(3):237-239.
31. Waisbord S, Larson H. Why Invest in Communication for Immunization: Evidence and Lessons Learned. A joint publication of the Health Communication Partnership based at Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (Baltimore) and the United Nations Children's Fund. New York; 2005.
32. Freeman BD. The Importance of Health Risk Communication in the Creation of the Anthrax Vaccine Immunization Program. Carlisle, PA: US Army War College; 2001.
33. Stein BD, Tanielian TL, Ryan GW, Rhodes HJ, Young SD, Blanchard JC. A bitter pill to swallow: nonadherence with prophylactic antibiotics during the anthrax attacks and the role of private physicians. Biosecur Bioterror 2004;2(3): 175-185.
34. Blanchard JC, Haywood Y, Stein BD, Tanielian TL, Stoto M, Lurie N. In their own words: lessons learned from those exposed to anthrax. Am J Public Health 2005 Mar;95(3):489-495.
35. Covello VT, Peters RG, Wojtecki JG, Hyde RC. Risk communication, the West Nile virus epidemic, and bioterrorism: responding to the communication challenges posed by the intentional or unintentional release of a pathogen in an urban setting. J Urban Health 2001 Jun;78(2):382-391.
36. Ratzan SC. Communicating risk: from crisis to calm. J Health Commun 2005 Mar;10(2):103-104.
37. Shore DA. Communicating in times of uncertainty: the need for trust. J Health Commun 2003;8(Suppl 1): 13-14.
38. Sorensen J. Risk communication and terrorism. Biosecur Bioterror 2004;2(3):229-231.
39. The Working Group on "Governance Dilemmas" in Bioterrorism Response. Leading during bioattacks and epidemics with the public's trust and help. Biosecur Bioterror 2004;2(1):25-40.
40. Peters RG, Covello VT, McCallum DB. The determinants of trust and credibility in environmental risk communication: an empirical study. Risk Anal 1997 Feb;17(1):43-54.
41. Trettin L, Musham C. Is trust a realistic goal of environmental risk communication? Environ Behav 2000 May 1, 2000;32(3):410-426.
42. Quinn SC, Thomas T, McAllister C. Postal workers' perspectives on communication during the anthrax attack. Biosecur Bioterror 2005;3(3):207-215.
43. Gursky E, Inglesby TV, O'Toole T. Anthrax 2001: observations on the medical and public health response. Biosecur Bioterror 2003;1(2):97-110.
44. Joellenbeck LM, Hernandez LM. The Institute of Medicine's independent scientific assessment of Gulf War health issues. Mil Med 2002 Mar;167(3):186-190.
45. North CS, Pollio DE, Pfefferbaum B, et al. Concerns of Capitol Hill staff workers after bioterrorism: focus group discussions of authorities' response. J Nerv Ment Dis 2005 Aug;193(8):523-527.
46. Quinn S, Thomas T, McAllister C. Lessons from the 2001 anthrax attack: a conceptual model for crisis and emergency risk communication. In: Seeger M, Sellnow T, Ulmer R, eds. Crisis Communication and the Public Health. Cresskill, NJ: Hampton Press; 2008:23-42.
47. Sandman PM. Anthrax, bioterrorism, and risk communication: guidelines for action. 2001. http://www.psandman.com/col/part1.htm. Accessed November 2, 2008.
48. Trenton Metro Area Local American Postal Workers Union AFL-CIO. Lab rat corner: anthrax. http://trentonmetroarealocal.com/lab-rat-corner.html. Accessed November 2, 2008.
49. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002 Oct;8(10):1138-1144.
50. Altman L. The doctor's world: in offering anthrax vaccine, officials admit to unknowns. New York Times December 25, 2001.
51. Connolly C, Goldstein A. Anthrax vaccine plan sows confusion; D.C. advises workers against treatment. Washington Post December 20, 2001;A01.
52. Connolly C. Vaccine plan revives doubts on anthrax policy. Washington Post December 24, 2001;A01.
53. Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T. African Americans' views on research and the Tuskegee syphilis study. Soc Sci Med 2001 Mar;52(5):797-808.
54. U.S. Centers for Disease Control and Prevention. Telebriefing transcript MMWR and anthrax update with Drs. Koplan, Sokas and Sanderson. December 20, 2001. www.cdc.gov/od/oc/media/transcripts/t011220.htm. Accessed November 2, 2008.
55. Covello VT. Best practices in public health risk and crisis communication. J Health Commun 2003;8(Suppl 1):5-8; discussion 148-151.
56. Blum J. Anthrax widespread at Brentwood; spores scattered farther through postal center than thought. Washington Post December 21, 2001;A20.
57. Blum J. Postal worker vaccinations to begin today; some Brentwood employees wary of experimental precaution against anthrax. Washington Post December 27, 2001;B2.
58. Connolly C, Goldstein A. Anthrax exposure estimates increased; first Capitol Hill aides receive vaccine shots. Washington Post December 21, 2001;A1.
59. Connolly C. Workers exposed to anthrax shun vaccine; low participation is blamed on confusing signals from U.S. health authorities. Washington Post January 8, 2002;A6.
60. Goldstein A. Postal workers to receive vaccine advice; health officials use video, doctor visits to sort out confusion over vaccine. Washington Post December 22, 2001;A11.
61. Goldstein A, Dewar H. Anthrax vaccine proves hard sell; postal employees opt for more pills. Washington Post December 23, 2001;A18.
62. Hanley R. A nation challenged: New Jersey; postal workers hesitant on anthrax vaccination. New York Times December 22, 2001.
63. Haughney C. Anthrax vaccine rejected. Washington Post January 4, 2002;A13.
64. A muddled message on anthrax vaccine [editorial]. New York Times December 20, 2001.
65. Rosenbaum D. A nation challenged: the disease: frustration at health agency over critics of anthrax policy. New York Times December 21, 2001.
66. Twomey S. Vaccine offer draws few postal workers; shots available as supplement to drugs in effort to prevent anthrax outbreaks. Washington Post December 28, 2001;A6.
67. Connolly C. CDC gets Pentagon's anthrax vaccine; officials to use medicine to treat those at risk for infection. Washington Post December 13, 2001;A10,
68. Stolberg S, Rosenbaum D. A nation challenged; U.S. will offer anthtax shots for thousands. New York Times December 19, 2001.
69. Connolly C, Vedantam S. U.S. offers anthrax vaccine to thousands; preparation used by military is unlicensed, controversial. Washington Post December 19, 2001;A3.
70. Stewart B. Union head objects to anthrax vaccine program. New York Times December 25, 2001.
71. Stolberg S. A nation challenged: steps against anthrax; civilians are reluctant to join US test of anthrax vaccine. New York Times January 8, 2002.
72. Double exposure [editorial]. Washington Post December 19, 2001;A38.
73. Vaccine offer raises new questions [editorial]. Washington Post December 23, 2001;A20.
74. Vedantam S. Anthrax vaccine mulled for up to 3,000 exposed; 'experimental' use likely to be controversial. Washington Post December 16, 2001;A33.
75. Vedantam S, Connolly C. Anthrax vaccine urged for Hill staff; health officials want inoculations to start this week. Washington Post December 18, 2001;A1.
76. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004 Oct 6;292(13):1593-1601.
77. Quinn S. Crisis and emergency risk communication in a pandemic: a model for building capacity and resilience of minority communities. Health Promotion Practice 2008;9(4Suppl):18S-25S.
78. Clarke L, Chess C, Holmes R, O'Neill KM. Speaking with one voice: risk communication lessons from the US anthrax attacks. Journal of Contingencies and Crisis Management 2006;14:160-169.
79. Martin SW, Tierney BC, Aranas A, et al. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. Pharmacoepi-demiol Drug Saf 2005 Jun; 14(6):393-401.
80. Sandman PM. Hazard versus outrage in the public perception of risk. In: Covello V, ed. Effective Risk Communication: The Role and Responsibility of Government and Nongovernmental Organizations. New York: Plenum Press;1989:45-49.
81. Rosenbaum D, Stolberg S. A nation challenged: the vaccine; as U.S. offers anthrax shots, safety debate begins again. New York Times December 20, 2001.